Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane

Experimental and Therapeutic Medicine

Volumn 1, Issue 3, 2010, Pages 445-451

  Huang, Cheng Long ^a   Kadota, Kyuichi ^a   Liu, Dage ^a   Ueno, Masaki ^b   Nakasima, Nariyasu ^a   Ishikawa, Shinya ^a   Gotoh, Masashi ^a   Misaki, Noriyuki ^a   Chang, Sung Soo ^a   Yokomise, Hiroyasu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Carboplatin; Chemotherapy; Class III tubulin; Excision repair cross complementing; Lung cancer; Taxane

Indexed keywords

BETA TUBULIN; CARBOPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CELL VIABILITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG HILUS; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MEDIASTINUM; MULTIMODALITY CANCER THERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR CELL;

EID: 77956220114     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000069     Document Type: Article

References (30)

1. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351-360, 2004.
2. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352: 2589-2597, 2005.
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M M: Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22: 3860-3867, 2004.
4. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R and Yokomise H: Clinical application of biological markers for treatments of resectable non-small cell lung cancers. Br J Cancer 92: 1231-1239, 2005.
5. Bepler G: Using translational research to tailor the use of chemotherapy in the treatment of NSCLC. Lung Cancer 50: S13-S14, 2005.
6. Huang C, Yokomise H, Fukushima M and Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2: 289-299, 2006.
7. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005.
8. Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H and Fukushima M: Evaluations of biomarkers associated with 5-FU sensitivity for non-small cell lung cancer patients postoperatively treated with UFT. Br J Cancer 95: 607-615, 2006.
9. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291, 2002.
10. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
11. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
12. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DDDD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
13. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A and Dumontet C: Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4: 2001-2007, 2005.
14. Mozzetti S, Ferlini C, Concolino P, et al: Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305, 2005.
15. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, Schittulli F and Lorusso V: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16 (Suppl 4): 14-19, 2005.
16. Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Nakashima T, Masuya D, Liu D and Huang CL: Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2,N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 133: 1179-1185, 2007.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. The Japanese Lung Cancer Society: Rule for Clinical and Pathological Record of Lung Cancer. 6th edition. Kanehara, Tokyo, pp168-169, 2003.
19. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C and Roig B: Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer. Cancer Control 10: 297-305, 2003.
20. Rigas JR: Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9: 16-23, 2004.
21. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001.
22. Burkhart CA, Kavallaris M and Horwitz SB: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: 1-9, 2001.
23. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
24. Katsetos CD, Legido A, Perentes E and Mork SJ: Class III β-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 18: 851-866, 2003.
25. Lu Q and Luduena RF: Removal of β-III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18: 173-182, 1993.
26. Kamath K, Wilson L, Cabral F and Jordan MA: β III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280: 12902-12907, 2005.
27. Derry WB, Wilson L, Khan IA, Luduena RF and Jordan MA: Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 36: 3554-3562, 1997.
28. Hari M, Yang H, Zeng C, Canizales M and Cabral F: Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 56: 45-56, 2003.
29. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M M and Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
30. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR: Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1998.